ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Budget Timetable Puts Pressure On Congress To Complete Appropriations Before Oct. 1

January 30, 1976

51% Control Rate Achieved In Phase II Trial of Elderly Patients

March 29, 2013

Grant Supplements, and Challenge Grants

February 20, 2009

Reversing Policy On Cancer Control Research, New Center Guidelines Top Accomplishments, Terry Believes

August 21, 1981

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

Longterm Followup Finds Taxotere Improves Survival

January 25, 2008